Six-month data from adult Cohort 4 show structural and functional improvements and a favorable safety profile; early safety data from pediatric Cohort 5 are consistent … The post Atsena Presents Positive Interim Six-Month Results from Part B of Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis appeared first on Atsena Therapeutics .